Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf319 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Thibaut Gelé und 14 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacie, AP-HP. Université Paris-Saclay, Hôpital Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Rifampin, Isoniazid, HIV Infections, Antitubercular Agents. Die Arbeit nennt 43 Literaturangaben. Gefördert von: ANRS, Maladies infectieuses émergentes, Médecins Sans Frontières.
Abstract (Originalsprache)
Background
Increasing rifampicin dosing is considered a potent strategy for shortening TB treatment duration. Although previous data among patients with HIV–TB coinfection has shown that doubling rifampicin dosing had a small effect on EFV concentrations, its effect on the pharmacokinetics (PK) of antituberculosis drugs remains lacking in this population.
Objectives
To compare the PK of rifampicin and isoniazid with and without EFV co-administration in patients with HIV–TB coinfection using two rifampicin dosing regimens (10 and 20 mg/kg/day) and EFV dosing (600 and 800 mg q24h).
Methods
Ninety-seven patients were assigned to three arms in a randomized clinical trial conducted in Uganda. Plasma concentrations of rifampicin, isoniazid, and acetyl-isoniazid were measured. PK parameters were estimated, and statistical comparisons were made using geometric mean ratios, 90% CIs and the pre-set 0.80–1.25 interval.
Results
Doubling rifampicin dosing increased its Cmax and AUClast almost 3-fold. Adding EFV decreased rifampicin AUClast by 34%–40%. Isoniazid AUClast was unaffected with EFV 600 mg q24h but decreased with EFV 800 mg q24h by 23%. EFV increased acetyl-isoniazid concentrations, suggesting enhanced acetylation activity. At 10 mg/kg of rifampicin, 88% of patients had Cmax below the therapeutic range. However, at 20 mg/kg of rifampicin, 87% of patients achieved therapeutic concentrations, ensuring effective treatment.
Conclusions
The study highlights the importance of adjusting rifampicin dosing to achieve therapeutic levels in patients with coinfection. Doubling rifampicin dosing in patients with HIV–TB coinfection increases the percentage of patients with Cmax within the therapeutic range. Additionally, while EFV slightly affects rifampicin and isoniazid PK, these changes are not clinically significant, supporting the efficacy and safety of the combined regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service de Pharmacie, AP-HP. Université Paris-Saclay, Hôpital Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.
- Epicentre, PO Box 1956, Mbarara, Uganda.
- SRF Research and Training Centres, PO Box 422317, Mbarara, Uganda.
- Epicentre-Médecins Sans Frontières, 34, avenue Jean Jaurès, 75019 Paris, France.
- Mbarara Regional Referral Hospital, Mbarara, Uganda.
- Service de Pharmacologie-Toxicologie, AP-HP. Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
ORCID-Profile: Thibaut Gelé, Winnie Muyindike, Maryline Bonnet, Aurélie Barrail-Tran
Förderung
- ANRS
- Maladies infectieuses émergentes
- Médecins Sans Frontières
Zitieren
APA
Gelé, T., Atwine, D., Baudin, E., Muyindike, W., Mworozi, K., Kyohairwe, R., Kananura, K., Logoose, S., Nyehangane, D., Nanjebe, D. K. T., Furlan, V., Taburet, A. M., Bonnet, M., Barrail-Tran, A., & ANRS12292 Rifavirenz study group (2025). Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf319
Vancouver
Gelé T, Atwine D, Baudin E, Muyindike W, Mworozi K, Kyohairwe R, et al. Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf319
BibTeX
@article{Gel2025,
author = {Gelé, Thibaut and Atwine, Daniel and Baudin, Elisabeth and Muyindike, Winnie and Mworozi, Kenneth and Kyohairwe, Racheal and Kananura, Keneth and Logoose, Susan and Nyehangane, Dan and Nanjebe, Deborah K T and Furlan, Valérie and Taburet, Anne-Marie and Bonnet, Maryline and Barrail-Tran, Aurélie and ANRS12292 Rifavirenz study group, ANRS12292 Rifavirenz study group},
title = {Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf319}
}
EUVIMED